AstraZeneca PLC Stock , AZNCF

	2023	2024	2025	2026	2027
Revenue	45,915	50,388	54,138	57,769	60,373
Dividend	3.05	3.16	3.31	3.43	3.69
Dividend Yield (in %)	2.34 %	2.43 %	2.54 %	2.63 %	2.83 %
EPS	7.24	8.74	9.81	10.85	11.79
P/E Ratio	18.27	15.12	13.48	12.18	11.21
EBIT	14,918	17,604	19,735	21,621	23,270
EBITDA	15,832	18,636	21,015	22,290	24,898
Net Profit	11,237	13,427	15,213	16,432	18,222
Net Profit Adjusted	11,237	13,427	15,213	16,811	18,222
Pre-Tax Profit	14,076	16,626	18,697	20,689	22,250
Net Profit (Adjusted)	8,500	11,224	13,483	15,512	17,806
EPS (Non-GAAP) ex. SOE	-	-	-	-	-
EPS (GAAP)	4.70	5.88	7.12	8.02	9.47
Gross Income	37,601	41,254	44,992	48,097	50,577
Cash Flow from Investing	-4,097	-3,860	-3,967	-3,876	-4,648
Cash Flow from Operations	11,652	14,022	16,255	17,465	20,852
Cash Flow from Financing	-7,361	-7,827	-7,386	-7,525	-7,820
Cash Flow per Share	7.46	8.77	9.88	9.68	12.42
Free Cash Flow	8,292	10,645	12,553	12,591	15,299
Free Cash Flow per Share	5.68	6.79	8.24	9.22	-
Book Value per Share	25.40	28.64	32.86	37.63	44.80
Net Debt	20,092	14,658	7,556	3,516	-10,477
Research & Development Exp.	10,133	10,784	11,346	11,975	12,043
Capital Expenditure	1,949	1,952	2,160	2,225	2,344
Selling, General & Admin. Exp.	14,504	14,917	15,300	15,084	15,739
Shareholder’s Equity	39,219	43,776	49,123	55,682	67,362
Total Assets	95,834	98,574	103,969	108,101	119,691

	Previous Quarter ending 12/31/22	Current Quarter ending 03/31/23	Next Quarter ending 06/30/23	Current Year ending 12/31/23	Next Year ending 12/31/24
Earnings Estimates
No. of Analysts	19	9	8	29	27
Average Estimate	1.343 USD	1.733 USD	1.723 USD	7.237 USD	8.744 USD
Year Ago	1.670 USD	1.890 USD	1.720 USD	6.660 USD	7.237 USD
Publish Date	2/9/2023	4/28/2023	7/27/2023	-	-
Revenue Estimates
No. of Analysts	19	10	9	27	26
Average Estimate	11,250 USD	10,790 USD	11,046 USD	45,915 USD	50,388 USD
Year Ago	12,011 USD	11,390 USD	10,771 USD	44,351 USD	45,915 USD
Publish Date	2/9/2023	4/28/2023	7/27/2023	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

AstraZeneca Dividend Calendar

Date	Name	Dividend	*yield	Currency
2022	AstraZeneca PLC	2.39	2.13	GBP
2021	AstraZeneca PLC	2.10	2.42	GBP
2020	AstraZeneca PLC	2.07	2.83	GBP
2019	AstraZeneca PLC	2.18	2.87	GBP
2018	AstraZeneca PLC	2.15	3.66	GBP
2017	AstraZeneca PLC	2.02	3.95	GBP
2016	AstraZeneca PLC	2.19	4.93	GBP
2015	AstraZeneca PLC	2.80	4.09	USD
2015	AstraZeneca PLC	1.89	4.08	GBP
2014	AstraZeneca PLC	1.78	3.91	GBP
2014	AstraZeneca PLC	2.80	3.95	USD
2013	AstraZeneca PLC	1.76	4.92	GBP
2013	AstraZeneca PLC	2.80	4.75	USD
2012	AstraZeneca PLC	1.79	6.14	GBP
2012	AstraZeneca PLC	2.80	6.08	USD
2011	AstraZeneca PLC	1.75	5.90	GBP
2011	AstraZeneca PLC	2.80	5.95	USD
2010	AstraZeneca PLC	2.55	5.52	USD
2010	AstraZeneca PLC	1.62	5.53	GBP
2009	AstraZeneca PLC	2.30	7.08	USD
2009	AstraZeneca PLC	1.41	4.86	GBP
2008	AstraZeneca PLC	2.05	4.77	USD
2007	AstraZeneca PLC	1.87	5.64	USD
2006	AstraZeneca PLC	1.72	4.09	USD
2005	AstraZeneca PLC	1.30	3.00	USD
2004	AstraZeneca PLC	0.94	3.25	USD
2003	AstraZeneca PLC	0.80	1.95	USD
2002	AstraZeneca PLC	0.70	2.06	USD
2001	AstraZeneca PLC	0.70	1.48	USD
2000	AstraZeneca PLC	0.70	1.35	USD
1999	AstraZeneca PLC	0.70	1.82	USD

*Yield of the Respective Date

AstraZeneca PLC Calendar

Event	Estimate	Info	Date
Annual General Meeting	-	Annual General Meeting	04/27/2023
Earnings Report	1.733 USD	Q1 2023 Earnings Release	04/28/2023
Earnings Report	1.723 USD	Q2 2023 Earnings Release	07/27/2023
Earnings Report	-	Q3 2023 Earnings Release	11/09/2023
Earnings Report	-	Q4 2023 Earnings Release	02/08/2024

AstraZeneca PLC Past Events

Event	Actual EPS	Info	Date
Earnings Report	1.380 USD	Q4 2022 Earnings Release	02/09/2023
Shareholders' Meeting	-	-	04/29/2022

AstraZeneca Profile

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

AstraZeneca Shareholder

Owner	in %
Freefloat	94.95
Government Pension Fund - Global (The)	2.32
Vanguard Health Care Fund	1.28
Vanguard Total International Stock Index Fund	1.26
American Funds EuroPacific Growth Fund	0.78
Goldman Sachs GQG Partners International Opportunities Fund	0.78

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

AstraZeneca Management

Name	Job
Jeffrey Pott	CHRO, Chief Compliance Officer & General Counsel
Michel Demaré	Chairman-Designate
Katarina Ageborg	Chief Compliance Officer & EVP-Sustainability
Cindy L. Hoots	Chief Digital & Information Officer
Pascal Soriot	Chief Executive Officer & Executive Director
Aradhana Sarin	Chief Financial Officer & Executive Director
Marc Pierre Jean Dunoyer	Chief Strategy Officer
Menelas NICOLAS Pangalos	EVP-Biopharmaceuticals Research & Development
Tyrell J. Rivers	Executive Director-Corporate Development
Ruud Dobber	Executive VP-Biopharmaceuticals Business
Susan Mary Galbraith	Executive VP-Oncology Research & Development
Pam P. Cheng	Executive VP-Operations & Information Technology
Iskra Reic	Executive Vice President-Europe & Canada
David Fredrickson	Executive Vice President-Oncology Business Unit
Jonathan Thomas Charles Slade	Group Treasurer
Kevin G. Lokay	Head-U.S. Immuno-oncology
Nazneen Rahman	Independent Non-Executive Director
Marcus Wallenberg	Independent Non-Executive Director
Tony Mok	Independent Non-Executive Director
Sherilyn D. McCoy	Independent Non-Executive Director
Deborah DiSanzo	Independent Non-Executive Director
Ahmed M. Hamdy	Member
Leif Valdemar Johansson	Non-Executive Chairman
Diana Layfield	Non-Executive Director
Andreas Rummelt	Non-Executive Director
Euan A. Ashley	Non-Executive Director
Regina Fritsche Danielson	SVP, Head-Research & Early Development
Adrian Charles Noel Kemp	Secretary
Sarah Miksinski	Senior Director-Global Regulatory Affairs
Philip Arthur John Broadley	Senior Independent Non-Executive Director
Margareta Elisabeth Björk	Senior VP & Head-Late-stage Development
Helen MacPhee	Vice President
Sjoerd Hubben	Vice President-Global Government Affairs & Policy